Manu Kaushik on Muck Rack

Manu Kaushik

Verified
New Delhi
As seen in: Financial Express, 7@7, BrandEquity.com, ET Healthworld, ETCISO, ETHRWorld, MSN India, The Economic Times, India Times, The Indian Express, Flipboard and
Journalist
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Manu

Contact Manu, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

‘This is only the beginning of the GLP-1 journey in India’: Vikrant Shrotriya, MD of Novo Nordisk India

|
By Manu Kaushik Verified
| Financial Express Verified
Danish drugmaker Novo Nordisk is banking on the low penetration of obesity and diabetes treatments in India to drive its next phase of growth for its GLP-1 and insulin businesses, even as competition from generic semaglutide brands intensifies. In an interview, Vikrant Shrotriya, managing director of Novo Nordisk India, tells Manu Kaushik that the GLP-1 market could finally exceed analysts’ estimates of Rs15,000 crore, while the number of insulin users could double over the next 6-7 years.
Open in Who Shared Issue with article?

India’s API self-reliance is still a long haul

|
By Manu Kaushik Verified
| Financial Express Verified
India’s drugmakers have a global repute, and they supply nearly half of all generic medicines sold at retail pharmacy outlets in the US. As soon as a new drug lost patent protection, they hit the market with acceptable-quality bioequivalent generic alternatives. However, this dexterity is not yet matched in the “bulk drugs” segment. A third of active pharmaceutical ingredients that go into formulations manufactured in the country are still being imported.
Open in Who Shared Issue with article?

Sales of anti-obesity drugs post first monthly decline as generic semaglutide-led growth loses steam

|
By Manu Kaushik Verified
| Financial Express Verified
About two months after the expiry of Novo Nordisk’s semaglutide patent in India that unleashed a flood of cheaper generic versions, the weight-loss drugs market has recorded decline in sales in June. According to Pharmarack, the monthly sales of GLP-1 drugs fell to Rs 227 crore last month from a record Rs 236 crore in May.
Open in Who Shared Issue with article?
See all 1,456 licensed articles (1,803 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified